Eli Lilly has announced that its accelerated approval bid for Alzheimer’s disease drug, donanemab, has been rejected by the FDA. The request was rejected on the grounds that a limited number of patients had at least 12 months of exposure to the drug throughout the company’s clinical trial.
Lilly was hoping that donanemab would be approved in order to treat early cases of symptomatic Alzheimer’s disease.
